[
  {
    "criterion": "Provides a correct CHA₂DS₂-VASc score calculation formula.",
    "axis": "accuracy",
    "point": 9
  },
  {
    "criterion": "Fails to provide any information about CHA₂DS₂-VASc score calculation.",
    "axis": "completeness",
    "point": -10
  },
  {
    "criterion": "Correctly explains the importance of considering the patient's recent stroke when calculating CHA₂DS₂-VASc score.",
    "axis": "context_awareness",
    "point": 8
  },
  {
    "criterion": "Advises against using low-molecular-weight heparin for bridging in patients with atrial fibrillation and a recent stroke.",
    "axis": "accuracy",
    "point": 9
  },
  {
    "criterion": "Does not provide any information about the ideal approach to bridging with low-molecular-weight heparin in patients with atrial fibrillation and a recent stroke.",
    "axis": "completeness",
    "point": -8
  },
  {
    "criterion": "Provides a clear and concise explanation of the CHA₂DS₂-VASc score calculation.",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Does not acknowledge the potential risks and benefits of using low-molecular-weight heparin for bridging in patients with atrial fibrillation and a recent stroke.",
    "axis": "context_awareness",
    "point": -6
  },
  {
    "criterion": "Provides a step-by-step guide on how to calculate CHA₂DS₂-VASc score.",
    "axis": "completeness",
    "point": 9
  },
  {
    "criterion": "Falsely states that low-molecular-weight heparin is always contraindicated in patients with atrial fibrillation and a recent stroke.",
    "axis": "accuracy",
    "point": -9
  }
]